Sam Brusco, Associate Editor05.28.21
Olympus completed the acquisition of Israeli medtech company Medi-Tate Ltd. it began in March, expanding its portfolio to include minimally invasive, in-office treatment for BPH. Medi-Tate's flagship iTind has both FDA de Novo authorization and CE mark certification. Olympus has been distributing iTind since November 2018 as a result of an intial investment.
The device, which provides non-ablative BPH treatment, aims to combat a condition that a great deal of men face in their lifetime. To treat it, a urologist implants the nitinol device in the prostate in a folded configuration. Over time, iTind expands and exerts pressure at three points to reshape the prostatic urethra and bladder neck. The implant is removed after five to seven days, leaving a wider opening for urine to flow. Unlike more invasive treatments, iTind allows patients to maintain sexual function.
iTind augments Olympus' BPH treatment portfolio that already touts resectoscopes and a variety of electrodes. The company's devices can now perform these procedures in office, ambulatory surgical center (ASC), and hospital environments.
“We believe Olympus appreciates our focus on long-term clinical results and dedication of the entire Medi-Tate team,” Medi-Tate CEO Ido Kilemnik told the press. We are pleased to be joining Olympus, which shares our vision of making iTind the global standard for BPH treatment. We are excited to be collaborating with Olympus in our effort to enhance the patients’ quality of life.”
The device, which provides non-ablative BPH treatment, aims to combat a condition that a great deal of men face in their lifetime. To treat it, a urologist implants the nitinol device in the prostate in a folded configuration. Over time, iTind expands and exerts pressure at three points to reshape the prostatic urethra and bladder neck. The implant is removed after five to seven days, leaving a wider opening for urine to flow. Unlike more invasive treatments, iTind allows patients to maintain sexual function.
iTind augments Olympus' BPH treatment portfolio that already touts resectoscopes and a variety of electrodes. The company's devices can now perform these procedures in office, ambulatory surgical center (ASC), and hospital environments.
“We believe Olympus appreciates our focus on long-term clinical results and dedication of the entire Medi-Tate team,” Medi-Tate CEO Ido Kilemnik told the press. We are pleased to be joining Olympus, which shares our vision of making iTind the global standard for BPH treatment. We are excited to be collaborating with Olympus in our effort to enhance the patients’ quality of life.”